Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them

AbstractDrug resistance can occur at the individual cellular level or as a result of properties of the tumor microenvironment. The convoluted vasculature within tumors results in robustly proliferating well-nourished cells located proximal to functional blood vessels and regions of slowly proliferating (often hypoxic) cells located distal to functional blood vessels. Irregular blood flow and large distances between functional blood vessels in solid tumors lead to poor drug distribution within them such that cells distal from functional blood vessels are exposed to ineffective concentrations of drug, resulting in therapeutic resistance. Strategies to improve or complement the distribution of anticancer drugs within tumors hold promise for increasing antitumor effects without corresponding increases in normal tissue toxicity. In particular, use of hypoxia-targeted agents and modulation of autophagy have shown promising results in enhancing the distribution of drug activity within solid tumors and hence antitumor efficacy. In this review, we describe causes of resistance to chemotherapy that relate to the microenvironment of solid tumors and the potential to improve antitumor effects by countering such mechanisms of resistance.

[1]  M. Borad,et al.  Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Gabizon,et al.  Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. , 2015, Anti-cancer drugs.

[3]  I. Tannock,et al.  Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302 , 2015, Clinical Cancer Research.

[4]  I. Tannock,et al.  Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy , 2015, British Journal of Cancer.

[5]  I. Tannock,et al.  A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin , 2014, Investigational New Drugs.

[6]  I. Tannock,et al.  Activity of the hypoxia‐activated pro‐drug TH‐302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy , 2014, International journal of cancer.

[7]  I. Tannock,et al.  Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors , 2013, Clinical Cancer Research.

[8]  I. Tannock,et al.  Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues , 2013, Cancer Chemotherapy and Pharmacology.

[9]  Qiang Zhang,et al.  The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. , 2013, Biomaterials.

[10]  I. Tannock,et al.  Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors , 2013, Molecular Cancer Therapeutics.

[11]  Thomas C. Chen,et al.  Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. , 2012, Cancer letters.

[12]  D. Klionsky,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) , 2012, Autophagy.

[13]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[14]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[15]  F. Sinicrope,et al.  The Role of Autophagy in Cancer: Therapeutic Implications , 2011, Molecular Cancer Therapeutics.

[16]  A. Giatromanolaki,et al.  Light-chain 3A autophagic activity and prognostic significance in non-small cell lung carcinomas. , 2011, Chest.

[17]  Xuejun Jiang,et al.  Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest. , 2011, Molecular cell.

[18]  S. Mendrinos,et al.  Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1 , 2011, Melanoma research.

[19]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[20]  K. Landfester,et al.  Omeprazole Inhibits Proliferation and Modulates Autophagy in Pancreatic Cancer Cells , 2011, PloS one.

[21]  H. Kuh,et al.  Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. , 2011, Oncology reports.

[22]  Gun-Hee Kim,et al.  Anti-/pro-apoptotic effects of hesperetin against 7,12-dimetylbenz(a)anthracene-induced alteration in animals. , 2011, Oncology reports.

[23]  S. Pattingre,et al.  Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells , 2010, Cell Death and Disease.

[24]  N. Ktistakis,et al.  Autophagosome formation in mammalian cells , 2010, Seminars in Immunopathology.

[25]  F. Lozupone,et al.  pH‐dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity , 2010, International journal of cancer.

[26]  Ian F Tannock,et al.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors , 2010, BMC Cancer.

[27]  Philippe Lambin,et al.  The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. , 2010, The Journal of clinical investigation.

[28]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[29]  A Tossavainen,et al.  Preparation of nanoparticle dispersions for in-vitro toxicity testing , 2009, Human & experimental toxicology.

[30]  H. Kuwano,et al.  Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells , 2009, Annals of Surgical Oncology.

[31]  Yongqiang Chen,et al.  Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3 , 2008, Autophagy.

[32]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[33]  M. Jäättelä,et al.  Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium , 2007, Cell Death and Differentiation.

[34]  P. Matarrese,et al.  Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. , 2007, Cancer research.

[35]  Timothy W Secomb,et al.  Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. , 2006, Journal of the National Cancer Institute.

[36]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[37]  I. Tannock,et al.  Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration , 2006, British Journal of Cancer.

[38]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[39]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[40]  Mark J. Ratain,et al.  Pharmacokinetic variability of anticancer agents , 2005, Nature Reviews Cancer.

[41]  K. Hahm,et al.  Selective Induction of Apoptosis with Proton Pump Inhibitor in Gastric Cancer Cells , 2004, Clinical Cancer Research.

[42]  C. Supuran,et al.  Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH , 2004, FEBS letters.

[43]  F. Lozupone,et al.  Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. , 2004, Journal of the National Cancer Institute.

[44]  P. Vaupel,et al.  Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.

[45]  A. Minchinton,et al.  Microregional Effects of Gemcitabine in HCT-116 Xenografts , 2004, Cancer Research.

[46]  T. Ueno,et al.  LC3 conjugation system in mammalian autophagy , 2004, The International Journal of Biochemistry & Cell Biology.

[47]  Peter Vaupel,et al.  Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.

[48]  A. Kimchi,et al.  Autophagy as a cell death and tumor suppressor mechanism , 2004, Oncogene.

[49]  I. Tannock,et al.  Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  M. Gassmann,et al.  Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  J. Bussink,et al.  Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. , 2002, International journal of radiation oncology, biology, physics.

[52]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  F. Rath,et al.  Tumor hypoxia, p53, and prognosis in cervical cancers. , 2001, International journal of radiation oncology, biology, physics.

[54]  A J Davis,et al.  Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. , 2000, The Lancet. Oncology.

[55]  A. Tomida,et al.  Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. , 2000, Cancer research.

[56]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[57]  J. Lankelma,et al.  Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[59]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[60]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[61]  Y. Ohsumi,et al.  Isolation and characterization of autophagy‐defective mutants of Saccharomyces cerevisiae , 1993, FEBS letters.

[62]  R K Jain,et al.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.

[63]  I. Tannock,et al.  Acid pH in tumors and its potential for therapeutic exploitation. , 1989, Cancer research.

[64]  R. Durand.  Distribution and activity of antineoplastic drugs in a tumor model. , 1989, Journal of the National Cancer Institute.

[65]  R K Jain,et al.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.

[66]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[67]  M C Ziskin,et al.  Growth of mammalian multicellular tumor spheroids. , 1983, Cancer research.

[68]  D. Hirst,et al.  TUMOUR CELL PROLIFERATION IN RELATION TO THE VASCULATURE , 1979, Cell and tissue kinetics.

[69]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[70]  G. Bjørkøy,et al.  Monitoring autophagic degradation of p62/SQSTM1. , 2009, Methods in enzymology.

[71]  Zhenhua Huang,et al.  The change of intracellular pH is involved in the cisplatin-resistance of human lung adenocarcinoma A549/DDP cells. , 2005 .

[72]  S. Grossman,et al.  The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study , 2004, Cancer Chemotherapy and Pharmacology.

[73]  I. Tannock,et al.  Tumor Physiology and Drug Resistance , 2004, Cancer and Metastasis Reviews.

[74]  R. Durand,et al.  Contribution of transient blood flow to tumour hypoxia in mice. , 1995, Acta oncologica.

[75]  M. Trotter,et al.  Evidence for intermittent radiobiological hypoxia in experimental tumour systems. , 1989, Biomedica biochimica acta.